Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review)

Molecular Medicine Reports

Volumn 4, Issue 2, 2011, Pages 203-208

  Aiello, Marco ^a   Vella, Nadia ^a   Cannavò, Calogero ^a   Scalisi, Aurora ^b   Spandidos, Demetrios A ^d   Toffoli, Giuseppe ^c   Buonadonna, Angela ^c   Libra, Massimo ^a   Stivala, Franca ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b AUSL 3   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Biological therapy; Colorectal cancer; Gene polymorphisms

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; FLUOROPYRIMIDINE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; OXALIPLATIN; OXALIPLATIN PLUS FLUOROURACIL; PANITUMUMAB; RAF PROTEIN; RAS PROTEIN; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEGRADATION KINETICS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; HUMAN; INTESTINE; LYMPH NODE; METASTASIS; MULTIMODALITY CANCER THERAPY; MUTATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; MUTATION; POLYMORPHISM, GENETIC;

EID: 79551712768     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.408     Document Type: Review

References (54)

1. Burt RW, Bishop DT, Lynch HT, Rozen P and Winawer SJ: Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 68: 655-665, 1990.
2. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM and Ederer F: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371, 1993. (Pubitemid 23131388)
3. Wingo PA, Tong T and Bolden S: Cancer statistics, 1995 CA Cancer J Clin 45: 8-30, 1995.
4. Tol J and Punt CJ: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther Mar 32: 437-453, 2010.
5. Duff SE, Jeziorska M, Rosa DD, et al: Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 42: 112-117, 2006. (Pubitemid 41814541)
6. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
7. Des Guetz G, Uzzan B, Nicolas P, et al: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94: 1823-1832, 2006.
8. Rajaganeshan R, Prasad R, Guillou PJ, et al: The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer 96: 1112-1117, 2007. (Pubitemid 46608318)
9. Jubb AM, Hurwitz HI, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217-227, 2006. (Pubitemid 46622051)
10. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006. (Pubitemid 44497237)
11. Goldstein NS and Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331-1346, 2001.
12. Spano JP, Lagorce C, Atlan D, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16: 102-108, 2005. (Pubitemid 40124486)
13. Zlobec I, Vuong T, Hayashi S, et al: A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 96: 793-800, 2007. (Pubitemid 46376624)
14. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008. (Pubitemid 351325672)
15. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007 (Pubitemid 46625066)
16. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008. (Pubitemid 351171687)
17. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al: The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 20: 879-884, 2009
18. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009
19. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998.
20. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007. (Pubitemid 46548951)
21. European Medicines Agency. Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Erbitux. http://www.emea.europa.eu/pdfs/human/opinion/Erbitux-28040208en. pdf. Accessed December 1, 2009
22. Tol J, Nagtegaal ID and Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99, 2009
23. Bibeau F, Lopez-Crapez E, Di Fiore F, et al: Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129, 2009.
24. Duff SE, Jeziorska M, Rosa DD, et al: Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer 42: 112-117, 2006. (Pubitemid 41814541)
25. Antonacopoulou AG, Tsamandas AC, Petsas T, et al: EGFR HER-2 and COX-2 levels in colorectal cancer. Histopathology 53: 698-706, 2008. (Pubitemid 352768714)
26. Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
27. Jung YD, Mansfield PF, Akagi M, et al: Effects of combination antivascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38: 1133-1140, 2002. (Pubitemid 34468020)
28. Shaheen RM, Ahmad SA, Liu W, et al: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85: 584-589, 2001. (Pubitemid 32808285)
29. Tonra JR, Deevi DS, Corcoran E, et al: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 12: 2197-2207, 2006.
30. Ciardiello F, Bianco R, Damiano V, et al: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747, 2000.
31. Tol J and Punt CJA: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 32: 437-453, 2010.
32. Zhang W, Gordon M, Schultheis AM, et al: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712-3718, 2007. (Pubitemid 47372612)
33. Weinshilboum R: Inheritance and drug response. N Engl J Med 348: 529-537, 2003.
34. Evans WE and McLeod H: Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549, 2003. (Pubitemid 36159890)
35. Goldstein DB: Pharmacogenetics in the laboratory and the clinic. N Engl J Med 348: 553-556, 2003.
36. Chen ZP, Malapetsa A, Monks A, et al: Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines. Ai Zheng 21: 233-239, 2002.
37. Park DJ, Stoehlmacher J, Zhang W, et al: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658, 2001. (Pubitemid 34013872)
38. Toffoli G, Cecchin E, Corona G, et al: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 3061-3068, 2006. (Pubitemid 46638941)
39. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002. (Pubitemid 34778092)
40. Stoehlmacher J, Ghaderi V, Iobal S, et al: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21: 3075-3079, 2001. (Pubitemid 33051178)
41. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
42. Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, Tumolo S, Masier S, Travail S, Boiocchi M and Toffoli G: Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 4: 11, 2004
43. Horie N, Aiba H, Oguro K, Hojo H and Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20: 191-197, 1995.
44. Pàez D, Parè L, Altès A, et al: Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. J Cancer Res Clin Oncol 136: 1681-1689, 2010.
45. Park JH, Kim NS, Park JY, et al: MGMT 2535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. J Cancer Res Clin Oncol 136: 1135-1142, 2010.
46. Rozen R: Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherti Metab Dis 19: 589-594, 1996.
47. Weisberg I, Tran P, Christensen B, Sibani S and Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64: 169-172, 1998. (Pubitemid 28453294)
48. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, et al: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69: 58-66, 2010.
49. Castillo-Fernándeza O, Santibáñezb M, Bauzab A, et al: Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res 41: 430-435, 2010.
50. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286, 2005. (Pubitemid 40590264)
51. Sartore-Bianchi A, Moroni M, Veronese S, et al: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238-3245, 2007. (Pubitemid 47325607)
52. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857, 2009.
53. Prenen H, De Schutter J, Jacobs B, et al: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15: 3184-3188, 2009.
54. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712, 2008.